Navigation Links
Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
Date:5/22/2009

BELLEVILLE, ON, May 22 /PRNewswire-FirstCall/ - Bioniche Life Sciences Inc. ("Bioniche"; TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, today provided an update on its Phase III clinical program evaluating Urocidin(TM) in the treatment of bladder cancer. On March 31st, the Company announced that recruitment had been completed in its initial Phase III registration trial evaluating Urocidin in the treatment of non-muscle-invasive bladder cancer that is refractory (unresponsive) to the current standard immunotherapy - Bacillus Calmette-Guerin (BCG).

The Data Safety Monitoring Committee (DSMC) held its eighth meeting regarding this clinical trial earlier this week. After its meeting, the Committee has recommended that Bioniche "continue the trial unmodified until the next scheduled or triggered meeting." The next scheduled meeting of the Committee is July.

The DSMC is an independent group that acts in an advisory capacity to the Company. Its role is to evaluate the progress of the clinical trial, including monitoring the safety and efficacy data generated in the trial. On a regular basis, the DSMC reviews study results, evaluates the incidence of adverse events, determines whether the basic trial assumptions remain valid, and evaluates whether the overall integrity, scientific merit and conduct of the study remain acceptable.

Data from the full cohort of 105 high-grade bladder cancer patients from this trial, coupled with additional safety information to be collected from a second clinical trial that is expected to start later this year, will be used to support regulatory submissions under the FDA's Accelerated Approval program.

Second Phase III Registration Trial

Bioniche plans to conduct a second registration trial that will directly compare the efficacy and safety of Urocidin with BCG in the first-line treatment of non-muscle-invasive bladder cancer. In September, 200
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Bioniche Reports Fiscal 2009 Third Quarter
2. Bioniche Provides a Corporate Update
3. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
4. Bioniche Revolving Credit Facility Maturity Date Amended
5. Bioniche Phase II Bladder Cancer Trial Results Published in The Journal of Urology
6. Bioniche Warrants Expiration Date to be Extended
7. Bioniche Reports Fiscal 2009 Second Quarter
8. Bioniche Invited to Participate in Canadian Beef Value Chain Roundtable
9. Bioniche Named One of the Top 50 Best Small and Medium Employers in Canada
10. Bioniche Presents MCC Data at the SIU World Uro-Oncology Update in Santiago, Chile
11. Bioniche Reports Fiscal 2009 First Quarter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... pm EDT): In a Viewpoint published today in the ... team of Boston researchers call for the implementation of ... United States. The researchers from the Friedman School of ... and Boston Children,s Hospital write that policies taxing nearly ... help people make meaningful dietary changes and substantially reduce ...
(Date:9/2/2014)... TCG, a leading government technology strategy and IT consultancy, ... fastest-growing companies in America for the seventh year in a ... in 2013, 2012, 2011, 2010, 2009, 2008, and the Inc. ... 2010 to 2013, ranking the company at position 3,708 on ... up 635 spots from 2013! More information is on ...
(Date:9/2/2014)... The use of Xarelto (known generically ... at a rapid pace, even as Xarelto lawsuits ... the U.S., Bernstein Liebhard LLP reports. According to a ... a year of its 2011 launch, patients were just ... blood thinner that has been in use for several ...
(Date:9/2/2014)... News) -- Complications are rare among breast cancer ... study indicates. However, the researchers did find ... slightly higher risk for certain complications than a ... 18,000 breast cancer patients who had a single ... reconstruction and were followed for 30 days after ...
(Date:9/2/2014)... September 2, 2014 In a large population-based ... found that mild cognitive impairment (MCI) occurred twice ... type 2. Interestingly, this strong association was only ... older participants (66-80 years) the association vanished. This ... Alzheimer,s Disease . , The concept of MCI ...
Breaking Medicine News(10 mins):Health News:Taxes and subsidies could encourage healthier diet and lower healthcare costs 2Health News:TCG One of the Fastest-Growing Companies in America – for the Eighth Time! 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 2Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 3Health News:Xarelto Lawsuit News: Bernstein Liebhard LLP Comments on Growing Use of Xarelto in Spite of Mounting Product Liability Litigation 4Health News:Complication Rates Low With Mastectomy, Breast Reconstruction: Study 2Health News:Diabetes mellitus and mild cognitive impairment: Higher risk in middle age? 2
... very practical agents in therapeutic applications. Researchers from ... Institute of Technology, writing Cancer Letters // (Available ... nanospheres as photothermal agent by selectively delivering gold ... a clinically related cancer biomarker, and discuss the ...
... true for the scientists who been working hard for the ... take an extra step ahead as it is likely to ... as their offspring, are safe to eat., ,Canada ... Canadian Scientists having proved themselves following the success regarding Starbuck, ...
... Publication, released on the 5th of October, which comprises ... has a comprehensive report on the threat of chronic ... Union Health Minister Dr Anbumani Ramadoss, the need to ... of chronic diseases in India was highlighted, stating that ...
... Sanofi Pasteur and Merck and found to be effective ... doses over 6 months which has shown 100% successful. The company ... protects against Human Papilloma virus infection and also genital warts, which ... market early next year and the profits would be great, and ...
... to regularly floss your teeth or so your dentist tells ... larger percentage of the population does not indulge in flossing. ... leads to gum problems including bleeding gums, receding gums and ... American Dental Association's (ADA) annual conference in Philadelphia says that ...
... for breast cancer patients, who show positive for Her-2/neu. ... positive, and they have a more resistant and active ... are Her-2/neu positive and the treatment for these patients ... not show any significant disease reduction. These patients should ...
Cached Medicine News:Health News:Gold Nanoparticles: Agents For Noninvasive Cancer Therapy 2Health News:Strategies to prevent the rising tide of the epidemic of chronic diseases 2Health News:Gardasil vaccine for cervical cancer 2
(Date:9/2/2014)... According to the new market research report ... Material (Metal, Glass, Plastic), by Application [GC, LC (HPLC, ... by MarketsandMarkets, the Chiral Chromatography Columns Market was valued ... at a CAGR of 5.2% from 2013 to reach ... market data tables and 15 figures spread through 135 ...
(Date:9/2/2014)... 2014  Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR ) ... the company at the Morgan Stanley Global Healthcare Conference in ... date: Tuesday September 9, 2014 , Presentation time: 5:15 ... 30-day archive of this presentation will be available at ... Avanir Pharmaceuticals, Inc. is a biopharmaceutical company focused on ...
(Date:9/2/2014)... 2014  EMD Serono, Inc., a subsidiary of Merck ... that Drew Young has joined the company ... capacity, he will be responsible for leading the strategic ... future products.   Bringing more than 20 years ... efforts at pharmaceutical and biotech companies, Mr. Young comes ...
Breaking Medicine Technology:Chiral Chromatography Column Market Worth $87.8 Million by 2018 2Chiral Chromatography Column Market Worth $87.8 Million by 2018 3Chiral Chromatography Column Market Worth $87.8 Million by 2018 4EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 2EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 3EMD Serono Appoints Drew Young to Senior Vice President, Neurology and Immunology 4
... that a new market research report is available in ... Drug Delivery System http://www.reportlinker.com/p0337136/Chinese-Markets-for--Drug-Delivery-System.html ... System has grown at a fast pace in the ... and demand will continue to grow. This new study ...
... 9, 2010 Reportlinker.com announces that ... catalogue: Prostate Cancer - Italy Drug ... http://www.reportlinker.com/p0332355/Prostate-Cancer---Italy-Drug-Forecasts-and-Treatment-Analysis-to-2020.html Prostate Cancer - Italy ... SummaryGlobalData,s pharmaceutical report, "Prostate Cancer - Italy Drug ...
Cached Medicine Technology:Reportlinker Adds Chinese Markets for Drug Delivery System 2Reportlinker Adds Chinese Markets for Drug Delivery System 3Reportlinker Adds Chinese Markets for Drug Delivery System 4Reportlinker Adds Chinese Markets for Drug Delivery System 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 2Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 3Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 4Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 5Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 6Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 7Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 8Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 9Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 10Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 11Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 12Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 13Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020 14
Two prong stainless steel tips; with titanium handle/...
Straight shafts with fine Pierse type tips on a 5mm platform; In Titanium...
Smooth colibri tip; In Titanium....
Gently curved 5mm Platform With 12, 0.12mm Teeth; In Titanium....
Medicine Products: